1069113-47-8

Usage

Uses

Used in Medicinal Chemistry:
(3aR,5r,6aS)-2-(tert-butoxycarbonyl)octahydrocyclopenta[c]pyrrole-5-carboxylic acid is utilized as a key intermediate in the synthesis of pharmaceuticals due to its unique structural features and the potential for further functionalization. Its Boc protecting group allows for selective reactions, making it a versatile building block in the creation of diverse bioactive molecules.
Used in Drug Development:
In the pharmaceutical industry, (3aR,5r,6aS)-2-(tert-butoxycarbonyl)octahydrocyclopenta[c]pyrrole-5-carboxylic acid serves as a precursor for the development of new drugs. Its carboxylic acid functionality can be exploited to form esters, amides, and other derivatives, which may possess specific biological activities or improved pharmacokinetic properties.
Used in Bioactive Compound Synthesis:
(3aR,5r,6aS)-2-(tert-butoxycarbonyl)octahydrocyclopenta[c]pyrrole-5-carboxylic acid is employed as a synthetic precursor for bioactive compounds, leveraging its structural attributes to create molecules with potential therapeutic effects. Its ability to be modified and incorporated into larger molecular frameworks makes it a valuable asset in the discovery of novel bioactive substances.

Upstream product

• 2049-80-1 (2-propenyl)propanedioic acid diethyl ester 
• 144296-43-5 diethyl 2-allyl-2-iodomalonate 
• 1068584-70-2 C₁₈H₂₉NO₆ 
• 146231-54-1 (3aR,6aS)-tert-butyl 5-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate 

Relevant academic research and scientific papers

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

Novel nicotinic acetylcholine receptor agonists containing carbonyl moiety as a hydrogen bond acceptor

A novel series of α4β2 nAChR agonists lacking common pyridine or its bioisosteric heterocycle have been disclosed. Essential pharmacophoric elements of the series are exocyclic carbonyl moiety as a hydrogen bond acceptor and secondary amino group within diaza- or azabicyclic scaffold. Computer modeling studies suggested that molecular shape of the ligand also contributes to promotion of agonism. Proof of concept for improving working memory performance in a novel object recognition task has been demonstrated on a representative of the series, 3-propionyl-3,7-diazabicyclo[3.3.0]octane (34).